Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

BH-30643

Small molecule · Inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (ERBB2) · developed by BlossomHill Therapeutics

Phase 1/2 Most advanced trial

BLSM Developer

1 Registered trials

What is BH-30643?

BH-30643 is an orally bioavailable, macrocyclic small molecule that reversibly binds and inhibits mutant-selective EGFR and HER2, including exon 20 insertion and resistance mutations, while largely sparing wild-type EGFR. It is being studied in advanced non-small cell lung cancer, alone and in combination with carboplatin and pemetrexed.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Targets: epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (ERBB2)
Mechanism: Inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (ERBB2)
Pathways: EGFR signaling, HER2 signaling, tumor cell proliferation, tumor vascularization
Therapy area: Oncology
Developer: BlossomHill Therapeutics (BLSM)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06706076	Phase 1/2	NSCLC (Advanced Non-small Cell Lung Cancer)	Recruiting	BLSM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

NSCLC (Advanced Non-small Cell Lung Cancer)

Other drugs acting on EGFR / ERBB2

Neratinib FDA approved Osimertinib FDA approved Trastuzumab Deruxtecan FDA approved Trastuzumab Emtansine FDA approved Zanidatamab FDA approved Actinium Ac 225 FPI-2068 Phase 1 ADCT-502 Phase 1 ALX2004 Phase 1 CGT4255 Phase 1 CUDC-101 Phase 1 EGFR-TKI inhibitor based on investigator's choice Phase 3 ELVN-002 Phase 1

More from BlossomHill Therapeutics

BH-30236 Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the BLSM page.

Follow BLSM, the company behind BH-30643

See BLSM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BLSM catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z